183 related articles for article (PubMed ID: 35086853)
21. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
22. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.
DeRyke CA; Kuti JL; Nicolau DP
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):337-44. PubMed ID: 17350206
[TBL] [Abstract][Full Text] [Related]
23. Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories.
Humphries RM; Abbott AN; Hindler JA
J Clin Microbiol; 2019 Jun; 57(6):. PubMed ID: 30971460
[TBL] [Abstract][Full Text] [Related]
24. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.
Morrissey I; Bouchillon SK; Hackel M; Biedenbach DJ; Hawser S; Hoban D; Badal RE
J Med Microbiol; 2014 Apr; 63(Pt 4):556-561. PubMed ID: 24478449
[TBL] [Abstract][Full Text] [Related]
26. Revision of fluoroquinolone breakpoints used for interpretation of antimicrobial susceptibility testing of canine bacterial isolates.
Papich MG; Gunnett LA; Lubbers BV
Am J Vet Res; 2023 Nov; 84(11):. PubMed ID: 37673214
[TBL] [Abstract][Full Text] [Related]
27. Effect of the 2014 Clinical and Laboratory Standards Institute urine-specific breakpoints on cefazolin susceptibility rates at a community teaching hospital.
Chastain DB; Ngando I; Bland CM; Franco-Paredes C; Hawkins WA
Ann Clin Microbiol Antimicrob; 2017 May; 16(1):43. PubMed ID: 28558707
[TBL] [Abstract][Full Text] [Related]
28. Evaluating outcomes associated with revised fluoroquinolone breakpoints for Enterobacterales urinary tract infections: A retrospective cohort study.
Benavides TM; Aden JK; Giancola SE
Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):741-749. PubMed ID: 35224677
[TBL] [Abstract][Full Text] [Related]
29. Antimicrobial susceptibility of Pseudomonas aeruginosa in China: a review of two multicentre surveillance programmes, and application of revised CLSI susceptibility breakpoints.
Xiao M; Wang Y; Yang QW; Fan X; Brown M; Kong F; Xu YC
Int J Antimicrob Agents; 2012 Nov; 40(5):445-9. PubMed ID: 22910455
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Lu PL; Liu YC; Toh HS; Lee YL; Liu YM; Ho CM; Huang CC; Liu CE; Ko WC; Wang JH; Tang HJ; Yu KW; Chen YS; Chuang YC; Xu Y; Ni Y; Chen YH; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S37-43. PubMed ID: 22749057
[TBL] [Abstract][Full Text] [Related]
31. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents.
Fedler KA; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):427-36. PubMed ID: 16938419
[TBL] [Abstract][Full Text] [Related]
32. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
Jones RN; Pfaller MA;
Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
[TBL] [Abstract][Full Text] [Related]
33. Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis.
Millar BC; McCaughan J; Rendall JC; Moore JE
Clin Respir J; 2021 Jan; 15(1):116-120. PubMed ID: 32790958
[TBL] [Abstract][Full Text] [Related]
34. Revisit of fluoroquinolone and azithromycin susceptibility breakpoints for Salmonella enterica serovar Typhi.
Das S; Ray U; Dutta S
J Med Microbiol; 2016 Jul; 65(7):632-640. PubMed ID: 27221661
[TBL] [Abstract][Full Text] [Related]
35. Revised ciprofloxacin breakpoints for Salmonella Typhi: its implications in India.
Balaji V; Sharma A; Ranjan P; Kapil A
Indian J Med Microbiol; 2014; 32(2):161-3. PubMed ID: 24713903
[TBL] [Abstract][Full Text] [Related]
36. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
[TBL] [Abstract][Full Text] [Related]
37. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial susceptibilities of the ertapenem-non-susceptible non-carbapenemase-producing Enterobacterales isolates causing intra-abdominal infections in the Asia-Pacific region during 2008-2014: Results from the Study for Monitoring the Antimicrobial Resistance Trends (SMART).
Jean SS; Hsueh PR;
J Glob Antimicrob Resist; 2020 Jun; 21():91-98. PubMed ID: 31627023
[TBL] [Abstract][Full Text] [Related]
39. Relative performance of antimicrobial susceptibility assays on clinical Escherichia coli isolates from animals.
Badger S; Abraham S; Saputra S; Trott DJ; Turnidge J; Mitchell T; Caraguel CGB; Jordan D
Vet Microbiol; 2018 Feb; 214():56-64. PubMed ID: 29408033
[TBL] [Abstract][Full Text] [Related]
40. Appropriateness of Empirical Fluoroquinolones Therapy in Patients Infected with
Wang Y; Zhang X; Wang X; Lai X
Infect Drug Resist; 2021; 14():3541-3552. PubMed ID: 34511945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
